Drugs / Sutetinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06010329 | Dec 2023 → Dec 2027 expected | non-small cell lung carcinoma | Teligene US | Recruiting | No outcome recorded |
| Phase 2 | NCT05168566 | Sep 2022 → Dec 2027 expected | non-small cell lung carcinoma | Teligene US | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sutetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06010329 ↗ |
| Action | Inhibit | “Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor.” NCT05168566 ↗ |
| Route | Oral | “Study drug to be taken orally with or without food (with food preferred) for up to13 cycles” NCT05168566 ↗ |
| Target | EGFR | “Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor.” NCT05168566 ↗ |